{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:32:23Z","timestamp":1787956343181,"version":"build-2784847793"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008725","name":"Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Depression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are frontline pharmacological strategies for the medical treatment of depression. In addition, approved by FDA in 2019, esketamine [as nasal spray; N-methyl-D-aspartate (NMDA) receptors antagonist with additional effects on \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, L-type voltage-dependent calcium channel (L-VDCC), opioid receptors, and monoaminergic receptors] is an essential compound in suicide and drug-resistant depression. However, the treatment of depression is burdened with severe side effects, and in many cases, it is ineffective. An equally important issue is the choice of antidepressant therapy in people with comorbid somatic diseases, for example, due to possible interactions with the patient's other drugs. Therefore, there is a great need for new antidepressants with different mechanisms of action and the need to refine the search for new substances. The purpose of this review was to discuss new research directions and new trends that dominate laboratories worldwide. We have reviewed the literature to present new points on the pharmacological target of substances with antidepressant activity. In addition, we propose a new perspective on depressive therapies.<\/jats:p>","DOI":"10.3389\/fphar.2022.988648","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T04:32:33Z","timestamp":1665117153000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["The treatment of depression \u2014 searching for new ideas"],"prefix":"10.3389","volume":"13","author":[{"given":"Katarzyna","family":"Stachowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sowa-Ku\u0107ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3892\/mmr.2021.12479","article-title":"Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (review)","volume":"24","author":"Abdel-Bakky","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B2","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5)","year":"2013"},{"key":"B3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1124\/jpet.108.142315","article-title":"Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism.","volume":"327","author":"Apparsundaram","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/bcp.13194","article-title":"SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn","volume":"83","author":"B\u00e9rard","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/mp.2016.144","article-title":"Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression","volume":"22","author":"Bouvier","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABAA receptors: Their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"B7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1192\/bjp.2021.44","article-title":"Time use and mental health in UK adults during an 11-week COVID-19 lockdown: A panel analysis","volume":"219","author":"Bu","year":"2021","journal-title":"Br. J. Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"100196","DOI":"10.1016\/j.ijchp.2020.07.007","article-title":"Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies","volume":"21","author":"Bueno-Notivol","year":"2021","journal-title":"Int. J. Clin. Health Psychol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"704281","DOI":"10.3389\/fcvm.2021.704281","article-title":"Antidepressant drugs effects on blood pressure","volume":"8","author":"Calvi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/NDT.S279342","article-title":"Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice","volume":"14","author":"Chauhan","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat ."},{"key":"B76","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-021-00846-5","article-title":"Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders","volume":"35","author":"Ceban","year":"2021","journal-title":"CNS Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota-gut-brain Axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12913-017-2106-6","article-title":"To what extent are psychiatrists aware of the comorbid somatic illnesses of their patients with serious mental illnesses? - a cross-sectional secondary data analysis","volume":"17","author":"Dornquast","year":"2017","journal-title":"BMC Health Serv. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14789450.2020.1772059","article-title":"The potential for metabolomics in the study and treatment of major depressive disorder and related conditions","volume":"17","author":"Duan","year":"2020","journal-title":"Expert Rev. Proteomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.crstbi.2021.10.001","article-title":"Role of actin cytoskeleton in the organization and function of ionotropic glutamate receptors","volume":"3","author":"Dutta","year":"2021","journal-title":"Curr. Res. Struct. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2007.09.008","article-title":"Efficacy of light therapy in nonseasonal depression: A systematic review","volume":"108","author":"Even","year":"2008","journal-title":"J. Affect. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.12740\/PP\/69660","article-title":"Mental and behavioural disorders in the ICD-11: Concepts, methodologies, and current status","volume":"51","author":"Gaebel","year":"2017","journal-title":"Psychiatr. Pol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamapsychiatry.2020.3650","article-title":"Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: A systematic review and meta-analysis.","volume":"78","author":"Guidi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.2174\/138161212803523617","article-title":"Genetics and personalized medicine in antidepressant treatment","volume":"18","author":"Gvozdic","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291720005358","article-title":"Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic","volume":"13","author":"Hawes","year":"2021","journal-title":"Psychol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejmech.2010.10.026","article-title":"Novel 4-aryl-pyrido[1, 2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 3","volume":"46","author":"Herold","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"B22","article-title":"Institute of health Metrics and evaluation","volume-title":"Global health data Exchange (GHDx)","year":"2019"},{"key":"B23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2012.12.008","article-title":"The inflammasome: Pathways linking psychological stress, depression, and systemic illnesses","volume":"31","author":"Iwata","year":"2013","journal-title":"Brain, Behav. Immun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"21501319221106625","DOI":"10.1177\/21501319221106625","article-title":"War Psychiatry: Identifying and managing the neuropsychiatric consequences of armed conflicts","volume":"13","author":"Jain","year":"2022","journal-title":"J. Prim. Care Community Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2000173118","DOI":"10.1073\/pnas.2000173118","article-title":"Multiple signaling pathways are essential for synapse formation induced by synaptic adhesion molecules","volume":"118","author":"Jiang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B26","doi-asserted-by":"publisher","first-page":"19ac13138","DOI":"10.4088\/JCP.19ac13138","article-title":"Not so fast. Recent successes and failures in treating depression","volume":"81","author":"Kadriu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"116778","DOI":"10.1016\/j.jns.2020.116778","article-title":"Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents.","volume":"412","author":"Kalmoe","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.redox.2012.10.001","article-title":"The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer","volume":"1","author":"Kansanen","year":"2013","journal-title":"Redox Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jad.2018.04.080","article-title":"Looking for bipolarity in antidepressant discontinuation manic states: Update and diagnostic consideration of the phenomenon","volume":"235","author":"Kassm","year":"2018","journal-title":"J. Aff. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/YCT.0000000000000733","article-title":"Combination of electroconvulsive therapy alternating with intravenous esketamine can lead to rapid remission of treatment resistant depression","volume":"37","author":"Kavakbasi","year":"2021","journal-title":"J. ECT."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","article-title":"Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials","volume":"26","author":"Kishi","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat ."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3390\/ijms22052329","article-title":"Synthesis of novel pyrido[1, 2-c]pyrimidine derivatives with 6-Fluoro-3-(4-piperidynyl)-1, 2-benzisoxazole moiety as potential SSRI and 5-ht1a receptor ligands.","volume":"22","author":"Kr\u00f3l","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ogc.2020.05.001","article-title":"Postpartum depression identification and treatment in the clinic setting","volume":"47","author":"Kroska","year":"2020","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/NDT.S157708","article-title":"Drug-drug interactions involving antidepressants: Focus on desvenlafaxine","volume":"14","author":"Low","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fncir.2013.00186","article-title":"Distinct roles of synaptic and extrasynaptic GABAAreceptors in striatal inhibition dynamics","volume":"7","author":"Luo","year":"2013","journal-title":"Front. Neural Circuits"},{"key":"B37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1124\/jpet.108.142307","article-title":"Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors","volume":"327","author":"Martin","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40263-022-00931-3","article-title":"Post-COVID-19 depressive symptoms: Epidemiology, pathophysiology, and pharmacological treatment","volume":"21","author":"Mazza","year":"2022","journal-title":"CNS Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC202105180","article-title":"Depression","volume":"174","author":"McCarron","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/ijnp\/pyab074","article-title":"Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial","volume":"25","author":"Mi","year":"2022","journal-title":"Int J Neuropsychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jocn.2021.07.023","article-title":"Investigating the potential mechanisms of depression induced-by COVID-19 infection in patients","volume":"91","author":"Mohammadkhanizadeh","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3389\/fpsyt.2019.00375","article-title":"COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders","volume":"10","author":"Muller","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"M\u00fcller","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"9594","DOI":"10.1073\/pnas.2000278117","article-title":"Seasonal changes in NRF2 antioxidant pathway regulates winter depression-like behavior","volume":"117","author":"Nakayama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B45","unstructured":"Neurosciences gate2022"},{"key":"B46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0896-6273(00)80517-6","article-title":"NSF binding to GluR2 regulates synaptic transmission","volume":"21","author":"Nishimune","year":"1998","journal-title":"Neuron"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.bmc.2004.11.019","article-title":"Novel, flexible, and conformationally defined analogs of gepirone: Synthesis and 5-ht1a, 5-ht2a, and D2 receptor activity","volume":"13","author":"Paluchowska","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): Finally, an FDA-approved treatment for postpartum depression","volume":"54","author":"Powell","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"9372182","DOI":"10.1155\/2019\/9372182","article-title":"Activators and inhibitors of NRF2: A review of their potential for clinical development","volume":"2019","author":"Robledinos-Anton","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fpsyt.2019.00605","article-title":"Neurobiology and therapeutic potential of cyclooxygenase-2 (COX-2) inhibitors for inflammation in neuropsychiatric disorders","volume":"10","author":"Sethi","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1113\/JP278702","article-title":"Functional interactions of ion channels with the actin cytoskeleton: Does coupling to dynamic actin regulate NMDA receptors?","volume":"599","author":"Shaw","year":"2021","journal-title":"J. Physiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"101943","DOI":"10.1016\/j.cpr.2020.101943","article-title":"The gut microbiota in anxiety and depression \u2013 a systemic review","volume":"83","author":"Simpson","year":"2021","journal-title":"Clin. Psych. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"249","DOI":"10.12932\/AP0803","article-title":"The potential impact of gut microbiota on your health: Current status and future challenges","volume":"34","author":"Sirisinha","year":"2016","journal-title":"Asian pac. J. Allergy Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0014-2999(99)00330-1","article-title":"Antidepressants for the new millennium","volume":"375","author":"Skolnick","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ejmech.2019.07.027","article-title":"Synthesis of new 5, 6, 7, 8-tetrahydropyrido[1, 2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands.","volume":"180","author":"\u015alifirski","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s43188-021-00098-x","article-title":"Trade\u2010offs between male fertility reduction and selected growth factors or the klotho response in a lipopolysaccharide-dependent mouse model","volume":"38","author":"Solek","year":"2021","journal-title":"Toxicol. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2478\/ahem-2021-0022","article-title":"Application potential of modulation of cyclooxygenase-2 activity: A cognitive approach","volume":"75","author":"Stachowicz","year":"2021","journal-title":"Postepy Hig. i Med. Doswiadczalnej"},{"key":"B59","doi-asserted-by":"publisher","first-page":"147660","DOI":"10.1016\/j.brainres.2021.147660","article-title":"Evidence for the interaction of COX-2 with mGluR5 in the regulation of EAAT1 and EAAT3 protein levels in the mouse hippocampus. The influence of oxidative stress mechanisms","volume":"1771","author":"Stachowicz","year":"2021","journal-title":"Brain Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"114729","DOI":"10.1016\/j.bcp.2021.114729","article-title":"Deciphering the mechanisms of regulation of an excitatory synapse via cyclooxygenase-2. A review","volume":"192","author":"Stachowicz","year":"","journal-title":"Biochem. Pharmacol."},{"key":"B61","first-page":"231","article-title":"Human mind under microbiom control","volume":"120","author":"Stachowicz","year":"2019","journal-title":"Wszechswiat"},{"key":"B62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.21307\/ane-2018-019","article-title":"The role of DSCAM in the regulation of synaptic plasticity: Possible involvement in neuropsychiatric disorders","volume":"78","author":"Stachowicz","year":"2018","journal-title":"Acta Neurobiol. Exp. (Wars)."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5514770","DOI":"10.1155\/2021\/5514770","article-title":"The combination of cognitive-behavioural therapy with virtual reality for the treatment of postnatal depression in a brief intervention context: A single-case study trial","volume":"2021","author":"Stamou","year":"2021","journal-title":"J. Healthc. Eng."},{"key":"B64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12888-020-02546-8","article-title":"Mental and somatic comorbidity of depression: A comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data","volume":"20","author":"Steffen","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","first-page":"151685","DOI":"10.1016\/j.acthis.2021.151685","article-title":"IGF-1 as selected growth factor multi-response to antidepressant-like substances activity in C57BL\/6J mouse testis model","volume":"123","author":"Tabecka-Lonczynska","year":"2021","journal-title":"Acta Histochem."},{"key":"B80","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","first-page":"pyv135","DOI":"10.1093\/ijnp\/pyv135","article-title":"Glucocorticoid receptors, brain-derived neurotrophic factor, serotonin and dopamine neurotransmission are associated with interferon-induced depression","volume":"19","author":"Udina","year":"2016","journal-title":"Oxf. Int. J. Neuropsychopharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/da.22217","article-title":"Major depressive disorder in DSM-5: Implications for clinical practice and research of changes from DSM-IV","volume":"31","author":"Uher","year":"2014","journal-title":"Depress. Anxiety"},{"key":"B68","doi-asserted-by":"publisher","first-page":"884143","DOI":"10.3389\/fphar.2022.884143","article-title":"Investigational drugs for the treatment of depression (part 1): Monoaminergic, orexinergic, GABA-ergic, and antiinflammatory agents","volume":"13","author":"Vasiliu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"884155","DOI":"10.3389\/fphar.2022.884155","article-title":"Investigational drugs for the treatment of depression (part 2): Glutamatergic, cholinergic, sestrin modulators and other agents","volume":"13","author":"Vasiliu","year":"","journal-title":"Front. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium","volume":"35","author":"V\u00e1zquez","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.arr.2012.08.004","article-title":"A breach in the scaffold: The possible role of cytoskeleton dysfunction in the pathogenesis of major depression","volume":"12","author":"Wong","year":"2013","journal-title":"Ageing Res. Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/96286","article-title":"Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders","volume":"53","author":"Woro\u0144","year":"2019","journal-title":"Psychiatr. Pol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"111736","DOI":"10.1016\/j.ejmech.2019.111736","article-title":"Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2, 5-dione derivatives with potential antidepressant effect.","volume":"183","author":"Wr\u00f3bel","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"705559","DOI":"10.3389\/fpsyt.2021.705559","article-title":"The effects and mechanisms of exercise on the treatment of depression","volume":"12","author":"Xie","year":"2021","journal-title":"Front. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.988648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T04:32:42Z","timestamp":1665117162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.988648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":79,"alternative-id":["10.3389\/fphar.2022.988648"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.988648","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"article-number":"988648"}}